Issues
-
Cover Image
Cover Image
About the Cover
Tissue and tumor vasculature needs to express appropriate “homing receptor ligands” to mediate the entry of T cells expressing “homing receptors” on their surfaces. The Engelhard laboratory investigated which homing receptors and tumor-expressed ligands are required for T-cell infiltration into tumors residing in different tissues. The tumor vasculature responded to the IFNγ. produced by activated T cells, upregulating particular ligands that allowed the accumulation of T cells expressing the appropriate homing receptors. The altered expression of their homing receptors on T cells, based on site of activation, creates a receptor-ligand recognition system that may be exploitable for clinical practice. Read more in Woods et al. in this issue of Cancer Immunology Research, starting on p. 1062. Fluorescence micrograph of an intraperitoneal tumor from Fig. 5C, with green depicting the vasculature. Artwork by Lewis Long. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Immunology Research
Cancer Immunology Research, launched in 2013 with Glenn Dranoff as founding Editor-in-Chief, is published by the AACR. The Journal illuminates the interplay between tumors and the immune system, with Robert D. Schreiber and Philip D. Greenberg serving as the Editors-in-Chief.
Table of Contents
Highlights from the Literature
Meeting Report
Research Articles
Interleukin-12 from CD103+ Batf3-Dependent Dendritic Cells Required for NK-Cell Suppression of Metastasis
Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy
Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
Acknowledgment to Reviewers
Journal Archive
Cancer Immunology Research
(2013-Present)Published monthly since 2013.
(ISSN 2326-6066)
Cancer Immunity
(2001-2013; volumes 1-13)Published periodically from 2001-2013.
(EISSN 1424-9634)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.